GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Glycorex Transplantation AB (NGM:GTAB B) » Definitions » EV-to-EBIT

Glycorex Transplantation AB (NGM:GTAB B) EV-to-EBIT : -19.14 (As of Jul. 08, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Glycorex Transplantation AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Glycorex Transplantation AB's Enterprise Value is kr163.89 Mil. Glycorex Transplantation AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-8.56 Mil. Therefore, Glycorex Transplantation AB's EV-to-EBIT for today is -19.14.

The historical rank and industry rank for Glycorex Transplantation AB's EV-to-EBIT or its related term are showing as below:

NGM:GTAB B' s EV-to-EBIT Range Over the Past 10 Years
Min: -550.65   Med: -24.29   Max: 287.2
Current: -19.14

During the past 13 years, the highest EV-to-EBIT of Glycorex Transplantation AB was 287.20. The lowest was -550.65. And the median was -24.29.

NGM:GTAB B's EV-to-EBIT is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 11.44 vs NGM:GTAB B: -19.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Glycorex Transplantation AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr156.26 Mil. Glycorex Transplantation AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was kr-8.56 Mil. Glycorex Transplantation AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -5.48%.


Glycorex Transplantation AB EV-to-EBIT Historical Data

The historical data trend for Glycorex Transplantation AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glycorex Transplantation AB EV-to-EBIT Chart

Glycorex Transplantation AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -104.96 -54.61 -33.76 -5.34 -14.45

Glycorex Transplantation AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.11 -2.90 -6.47 -14.45 -18.25

Competitive Comparison of Glycorex Transplantation AB's EV-to-EBIT

For the Biotechnology subindustry, Glycorex Transplantation AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's EV-to-EBIT falls into.


;
;

Glycorex Transplantation AB EV-to-EBIT Calculation

Glycorex Transplantation AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=163.888/-8.562
=-19.14

Glycorex Transplantation AB's current Enterprise Value is kr163.89 Mil.
Glycorex Transplantation AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB  (NGM:GTAB B) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Glycorex Transplantation AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-8.562/156.26322
=-5.48 %

Glycorex Transplantation AB's Enterprise Value for the quarter that ended in Mar. 2025 was kr156.26 Mil.
Glycorex Transplantation AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-8.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glycorex Transplantation AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Glycorex Transplantation AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Glycorex Transplantation AB Business Description

Traded in Other Exchanges
Address
Solvegatan 41, Lund, SWE, 223 70
Glycorex Transplantation AB is a biotechnology company. The company is involved in the development, production, and sales of organ transplantation. Its product includes Glycosorb-ABO which facilitates the transplantation of organs over the blood group barriers. The group has more than 130 transplant centers in approximately 23 countries.

Glycorex Transplantation AB Headlines

No Headlines